A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate
Open Access
- 1 August 2019
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 8065-8072
Abstract
Purpose: Intravenous (IV) sodium bicarbonate is typically used in alkalization regimens for the safe use of the chemotherapeutic agent high-dose methotrexate (HDMTX). Urine parameters including urine output and pH are important in order to minimize the risk of kidney injury, which increases adverse effects and hospital length of stay following HDMTX. IV sodium bicarbonate has been on shortage, and there are limited literature describing the safety of alternative regimens. Patients and methods: A single institution, prospective analysis of non-Hodgkin’s lymphoma and acute lymphoblastic leukemia patients receiving HDMTX for central nervous system (CNS) prophylaxis or disease. Patients received an oral (PO) regimen of sodium bicarbonate and acetazolamide to achieve a urine pH >7. This cohort was compared to a subsequent IV sodium bicarbonate control cohort. Multiple co-primary safety outcomes assessed the incidences of acute kidney injury and delayed methotrexate clearance as well as change in liver function tests. Secondary outcomes included time to urine pH, time to urine output, and length of stay. Results: A total of 126 encounters were studied for the primary safety outcome. There was no difference between AKI incidence in patients receiving the PO alkalization regimen compared to patients receiving IV sodium bicarbonate (14.5% vs 9.3%, respectively, P=0.41). There was no difference in methotrexate clearance between the PO and IV groups (26.5% vs 37.2%, respectively, P=0.21). The use of PO alkalization regimen is estimated to have saved 2002 vials of IV sodium bicarbonate and was approximately US$226 less expensive per encounter. Conclusion: This analysis supports the use of PO regimens to achieve urine alkalization necessary for safe administration of HDMTX during periods of IV sodium bicarbonate shortage. Further studies may determine optimal dosing strategies that decrease length of stay and ensure noninferiority of efficacy outcomes with PO regimens for urine alkalization with HDMTX.Keywords
This publication has 17 references indexed in Scilit:
- Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexateJournal of Oncology Pharmacy Practice, 2016
- Substitution of sodium acetate for sodium bicarbonate for urine alkalinization in high-dose methotrexate therapyAmerican Journal of Health-System Pharmacy, 2015
- Drug Shortages: A Complex Health Care CrisisMayo Clinic Proceedings, 2014
- KDIGO Clinical Practice Guidelines for Acute Kidney InjuryNephron Clinical Practice, 2012
- Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonateJournal of Oncology Pharmacy Practice, 2011
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- Understanding and Managing Methotrexate NephrotoxicityThe Oncologist, 2006
- Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexateCancer Chemotherapy and Pharmacology, 1991
- The Pharmacology and Clinical Use of MethotrexateNew England Journal of Medicine, 1983
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976